Fda Bcs
Aug 9, 2018 - Therefore, a direct reference to biopharmaceutics classification system (BCS) class 1 and class 3 is not necessary because permeability.
Multisource (generic) products must satisfy the same standards as those applied to originator products. The manufacturer of a multisource (generic product) must demonstrate that its product:. satisfies the same standards as those applicable to the innovator product. provide assurance that it is clinically interchangeable with, i.e. Therapeutically equivalent or bioequivalent to, the innovator product.
The manufacturer may therefore need to carry out a bioequivalence study: the data generated should provide a bridge between the (innovator) product for which safety and efficacy data are available and the generic products for which such data are not available. The WHO Technical Report Series (TRS) contain a number of annexes that manufacturers can consult regarding registration requirements for establishing the interchangeability of a multisource product with its comparator product, which is not normally the innovator product. These requirements must be met by any multisource product that is submitted for prequalification. In some cases, it may be possible to request that the requirement to conduct an in vivo study to establish bioequivalence be waived. The topic of biowaivers is discussed below. Design of bioequivalence studies The WHO Prequalification Team: medicines (PQTm) supports applicants in addressing specific scientific issues related to product development and design of bioequivalence studies that are intended to support an application for prequalification. It strongly recommends that applicants submit the final draft of their bioequivalence study protocol for review before embarking on the study.
The FDA issued a guidance for industry on waivers of in vivo bioavailability and bioequivalence studies for IR solid oral-dosage forms based on the BCS in August 2000 (5). The Biopharmaceutics Classification System (BCS) is a scientific framework that is based on the aqueous solubility and intestinal permeability of the drug substance. It classifies the drug.
Questions on bioequivalence studies or final draft protocols can be sent to the. Comparator products for bioequivalence studies The quality, safety and efficacy of the innovator product, which was first authorized for marketing, were fully assessed and documented in pre-marketing studies and post-marketing monitoring schemes. The innovator product is therefore the most logical comparator product to use for establishing interchangeability. Indeed, a generic pharmaceutical product should not be used as a comparator if an innovator product is available for this purpose. The risk with using a generic pharmaceutical product as a comparator is that similarity of future multisource products becomes progressively less reliable leading to a lack of interchangeability with the innovator. WHO has compiled lists of comparator products that are recommended for use in bioequivalence studies that aim to generate data for demonstrating bioequivalence of products invited for evaluation. Questions relating to bioequivalence or choice of comparator products outside the recommended lists, can be submitted to Dr Matthias Stahl at before the start of any bioequivalence study.
Selection of a comparator Comparator products should be purchased from a well-regulated market within the jurisdiction of a stringent regulatory authority (SRA). An SRA is the regulatory authority of a country officially participating in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Mortal kombat vs dc download. The current ICH members are Canada, the European Union, Japan, Switzerland and the USA. Other countries associated with ICH (through legally binding mutual recognition agreements) include Australia, Norway, Iceland and Liechtenstein. If no WHO-recommended comparator product can be identified, or if the selected WHO-recommended comparator product cannot be obtained from a well-regulated market falling within the jurisdiction of a stringent regulatory authority, the applicant should consult the WHO Prequalification Team: medicines regarding the choice of comparator, before initiating a study.
The dose of the invited product may differ from that of the available recommended acceptable comparator product. It is not necessarily the case in such instances that a bioequivalence study at the same dose level will be required. Instead, if the active substance shows linear pharmacokinetics, extrapolation, applied by dose normalization, may generate sufficient data for submission to WHO. Demonstrating bioequivalence of fixed-dose combination products The bioequivalence of fixed-dose combination (FDC) should be established following the same general principles as those described above. The submitted FDC product should be compared with the respective innovator FDC product.
If no innovator FDC product is available on the market, individual component products administered in loose combination should be used as comparators. Information on comparator product to be included in product dossier The generic finished pharmaceutical product dossier submitted for full assessment should include the following information on the comparator product:. country of origin. lot number and expiry date.
Fda Bcs Guidance
results of pharmaceutical analysis to prove pharmaceutical equivalence. Waiver request for a bioequivalence study A manufacturer may request a waiver of the requirement for submission of an in vivo bioequivalence study for an immediate release oral dosage form. A biowaiver is the term used to describe a regulatory drug approval process whereby the efficacy and safety part of a dossier (application) is approved based on evidence of equivalence other than through in vivo equivalence testing. For solid oral dosage forms, biowaivers may be possible based on the Biopharmaceutics Classification System (BCS) or on the proportionality of the formulation of a product to the formulation of another strength of that product (an additional strengths biowaiver). BCS-based biowaivers Currently, WHO uses a two-pronged process for this type of biowaiver. For certain invited APIs, the BCS class of the API is well defined and only data regarding the FPP in comparison to the comparator product is required for the biowaiver application. For other APIs, a biowaiver application will require sufficient data to classify the API within the BCS, as well as data regarding the FPP in comparison to the comparator product.
General information on BCS-based biowaiver applications, including a list of APIs for which classification data is not required, can be found in the prequalification guidance document General notes on Biopharmaceutics Classification System (BCS)-based biowaiver applications. All BCS-based biowaiver applications should include a completed Biowaiver application form: Biopharmaceutics Classification System in MS Word format. Additional strength biowaivers Any application for a biowaiver for an additional strength of a submitted (test) product, based on proportionality of formulations and comparative in vitro dissolution data, must include data on comparative dissolution between the different strengths of the test product in the three physiological pH media and the release medium, if different. All additional strength biowaiver applications should include a completed Biowaiver application form: Additional strengths in MS Word format.
. 1.5k Downloads.
Abstract The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies. In 2000, the US-FDA was the first regulatory agency to publish guidance for industry describing how to meet criteria for requesting a waiver of in vivo bioavailability and bioequivalence studies for highly soluble, highly permeable (BCS Class I) drugs. Subsequently, the World Health Organization (WHO) and European Medicines Agency (EMA) published guidelines recommending how to obtain BCS biowaivers for BCS Class III drugs (high solubility, low permeability), in addition to Class I drugs. In 2015, the US-FDA became better harmonized with the EMA and WHO following publication of two guidances for industry outlining criteria for obtaining BCS biowaivers for both Class I and Class III drugs. A detailed review and comparison of the BCS Class I and Class III criteria currently recommended by the US-FDA, EMA, and WHO revealed good convergence of the three agencies with respect to BCS biowaiver criteria. The comparison also suggested that, by applying the most conservative of the three jurisdictional approaches, it should be possible for a sponsor to design the same set of BCS biowaiver studies in preparing a submission for worldwide filing to satisfy US, European, and emerging market regulators. It is hoped that the availability of BCS Class I and Class III biowaivers in multiple jurisdictions will encourage more sponsors to request waivers of in vivo bioavailability/bioequivalence testing using the BCS approach.